Intracolonically administered adeno-associated virus-bone morphogenetic protein-7 ameliorates dextran sulphate sodium-induced acute colitis in rats

Journal of Gene Medicine

Volumn 14, Issue 7, 2012, Pages 482-490

  Hao, Zhiming ^a   Yang, Xiaofei ^a   Lv, Yifei ^a   Li, Shuang ^a   Purbey, Bibek Kumar ^a   Su, Houqiang ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Adeno associated virus; Bone morphogenetic protein 7; Dextran sulphate sodium; Intracolonic administration; Ulcerative colitis

Indexed keywords

BETA GALACTOSIDASE; DEXTRAN SULFATE; ENHANCED GREEN FLUORESCENT PROTEIN; MALONALDEHYDE; MYELOPEROXIDASE; PARVOVIRUS VECTOR; RECOMBINANT OSTEOGENIC PROTEIN 1; SUPEROXIDE DISMUTASE;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLUMINESCENCE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX; ENZYME ACTIVITY; FEMALE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ULCERATIVE COLITIS; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; CELL PROLIFERATION; COLITIS, ULCERATIVE; COLON; DEPENDOVIRUS; DEXTRAN SULFATE; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SPECIFIC PATHOGEN-FREE ORGANISMS;

ADENO-ASSOCIATED VIRUS; RATTUS;

EID: 84864312733     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2642     Document Type: Article

References (35)

1. Ekbom A. The epidemiology of IBD. Inflamm Bowel Dis 2004; 10(Suppl 1): S32-S34.
2. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12: S3-S9.
3. Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009; 15: 935-950.
4. Kucharzik T, Maaser C, Lügering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006; 12: 1068-1083.
5. Maric I, Poljak L, Zoricic S, et al. Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol 2003; 196: 258-264.
6. Wells RG. BMP-7: a new TGF-β family member takes the stage in colitis treatment. Inflamm Bowel Dis 2004; 10: 169.
7. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133-146.
8. Boon MR, van der Horst G, van der Pluijm G, et al. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev 2011; 22: 221-229.
9. Weiskirchen R, Meurer S, Gressner AM, et al. BMP-7 as antagonist of organ fibrosis. Front Biosci 2009; 14: 4992-5012.
10. Flier SN, Tanjore H, Kokkotou EG, et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010; 285: 20202-20212.
11. Vukicevic S, Basic V, Rogic D, et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998; 102: 202-214.
12. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249.
13. Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease: mucosal immune responses and protection by tolerance. J Immunol 1996; 157: 2174-2185.
14. Ohkawara T, Nishihira J, Takeda H, et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002; 123: 256-270.
15. Fiocchi C. TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001; 108: 523-526.
16. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110: 975-984.
17. Xian CJ, Xu X, Mardell CE, et al. Site-specific changes in transforming growth factor-alpha and -beta1 expression in colonic mucosa of adolescents with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 591-600.
18. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-609.
19. Wiercińska-Drapalo A, Flisiak R, Prokopowicz D. Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1. Cytokine 2001; 14: 343-346.
20. Fiocchi C. TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001; 108: 523-526.
21. Stadnicki A, Machnik G, Klimacka-Nawrot E, et al. Transforming growth factor-β1 and its receptors in patients with ulcerative colitis. Int Immunopharm 2009; 9: 761-766.
22. Kiliç ZM, Ayaz S, Ozin Y, Nadir I, Cakal B, Ulker A. Plasma transforming growth factor-β1 level in inflammatory bowel disease. Turk J Gastroenterol 2009; 20: 165-170.
23. Krishnan K, Arnone B, Buchman A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm Bowel Dis 2011; 17: 410-422.
24. Feagins LA. Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis 2010; 16: 1963-1968.
25. Hamady ZZR, Scott N, Farrar MD, et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan. Inflamm Bowel Dis 2011; 17: 1925-1935.
26. Mukoyama T, Kanbe T, Murai R, et al. Therapeutic effect of adenoviral-mediated hepatocyte growth factor gene administration on TNBS-induced colitis in mice. Biochem Biophys Res Commun 2005; 329: 1217-1224.
27. Motta JP, Magne L, Descamps D, et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011; 140: 1272-1282.
28. Lv Y, Yang X, Huo Y, et al. Adenovirus-mediated hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein suppresses dextran sulfate sodium-induced acute ulcerative colitis in rats. Inflamm Bowel Dis 2012; DOI: 10.1002/ibd.22887
29. Berns KI, Hauswirth WW. Adeno-associated virus. Adv Virus Res 1979; 25: 407-449.
30. van der Laan LJW, Wang Y, Tilanus HW, et al. AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? Exp Opin Biol Ther 2011; 11: 315-327.
31. During MJ, Xu R, Young D, et al. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 1998; 4: 1131-1135.
32. During MJ, Symes CW, Lawlor PA, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000; 287: 1453-1460.
33. Polyak S, Mah C, Porvasnik S, et al. Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig Dis Sci 2008; 53: 1261-1270.
34. Peng J, Wang H, Ma Y, Wu X, et al. Non-invasive viral gene transfer of factor IX to colonic epithelial cells in haemophilia B mice. J Thromb Haemost 2008; 6: 1033-1035.
35. Polyak S, Mach A, Porvasnik S, et al. Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis. Am J Physiol Gastrointest Liver Physiol 2012; 302: G296-G308.